Treatment of type 2 diabetes

Abstract

The invention relates to the use of a monoamine neurotransmitter re-uptake inhibitor comprising a 2,3-disubstituted tropane moiety, or a tautomer, a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof for the manufacture of a medicament for the treatment of diabetic patients.

1. A method for the treatment of Type 2 diabetes, which method comprises administration to a patient in need thereof effective amounts of the compound of formula (IA): 
       
         
           
           
               
               
           
         
         a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof. 
       
     
     
       2. The method according to  claim 1 , wherein the dosage amount of said compound of formula (IA) is administered from 0.05 to 10 mg daily. 
     
     
       3. The method according to  claim 1 , wherein said compound of formula (IA) is administered by an oral, injectable, transdermal or rectal route. 
     
     
       4. The method according to  claim 1 , wherein said compound of formula (IA) lowers the HbA1c value in a diabetic patient. 
     
     
       5. The method according to  claim 1 , wherein said compound of formula (IA) is administered in fixed or free combination with at least one antidiabetic agent that treats Type 2 diabetes. 
     
     
       6. The method according to  claim 1 , wherein said compound of formula (IA) is administered in combination with Rimonabant. 
     
     
       7. A method for lowering HbA1c values in a diabetic patient, which method comprises administration to a patient in need thereof effective amounts of the compound of formula (IA): 
       
         
           
           
               
               
           
         
         a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof. 
       
     
     
       8. The method according to  claim 7 , wherein the administration is an oral, injectable, transdermal or rectal route, the dosage amount of said compound of formula (IA) is from 0.05 to 10 mg daily, and the compound of formula (IA) is administered in fixed or free combination with at least one antidiabetic agent that treats Type 2 diabetes. 
     
     
       9. The method according to  claim 7 , wherein HbA1c is lowered in said patient by at least 0.5% within 6 months of administration. 
     
     
       10. A method for the treatment of Type 2 diabetes, which method comprises administration to a patient in need thereof effective amounts of the compound of formula (IA) 
       
         
           
           
               
               
           
         
         a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof; 
         wherein said compound of formula (IA) is administered in combination with Rimonabant. 
       
     
     
       11. The method according to  claim 10 , wherein the dosage amount of said compound of formula (IA) is administered from 0.05 to 10 mg daily. 
     
     
       12. The method according to  claim 10 , wherein said compound of formula (IA) is administered by an oral, injectable, transdermal or rectal route. 
     
     
       13. The method according to  claim 10 , wherein said compound of formula (IA) lowers the HbA1c value in a diabetic patient.